Gregg Gilbert

Key recent clinical pipeline developments have prompted an analyst at Truist Securities to turn bullish on pharma giant Bristol-Myers Squibb Company (NYSE: BMY). The Bristol-Myers Squibb Analyst: Gregg Gilbert upgraded Bristol-Myers Squibb from Hold to Buy and increased the price target from $66...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) fell 20 percent after reporting in-line earnings results. But the very news that catalyzed a selloff was well-received by one longtime Valeant bear who transformed into a bull Monday. The Rating Deutsche Bank analyst Gregg Gilbert ...

Analysts at Deutsche Bank see a scenario in which Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock can move higher from its current levels but are simultaneously no longer recommending investors be buying the stock. The firm's Gregg Gilbert downgraded Teva's stock from Buy...

After a more than 15-percent gain in Zoetis Inc (NYSE: ZTS) since the start of 2017, analysts at Deutsche Bank see little incremental upside in the near-term. Gregg Gilbert downgraded Zoetis' stock from Buy to Hold with an unchanged $65 price target as it has handily outperformed the S&P...

A Bloomberg article Friday suggested that the European company Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS) is considering a bid for Akorn, Inc. (NASDAQ: AKRX). While there is lack of certainty regarding whether such a deal would materialize and at what price, “we continue to believe...

A Reuters article, published on March 7 suggested that Impax Laboratories Inc (NASDAQ: IPXL) hired an investment bank to help it explore strategic options, which could include an acquisition or sale of the company. “We believe patient investors could be rewarded if business trends improve, or...

Deutsche Bank downgraded Akorn, Inc. (NASDAQ: AKRX) to Hold from Buy as the stock has recovered since the post-third quarter correction. According to Deutsche Bank, further upside will depend on “hard-to-call dynamics of new product approvals vs. base business erosion.” Akorn has a...

Gregg Gilbert of Deutsche Bank would be surprised if Pfizer Inc. (NYSE: PFE) approaches Bristol-Myers Squibb Co (NYSE: BMY) with a takeover bid at this stage. The brokerage issued the comment after Street Insider said Roche Holding Ltd. (ADR) (OTC: RHHBY), Novartis AG (ADR) (NYSE: NVS)and Pfizer...

“The district court ruled against Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) in the Copaxone 40mg patent case, invalidating each of the four patents in the case,” Deutsche Bank’s Gregg Gilbert said in a note, while maintaining a Buy rating on the company, with a price...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced that Dipankar Bhattacharjee, the CEO of Teva generics Europe, has been appointed as the new head of global generics. Deutsche Bank’s Gregg Gilbert maintains a Buy rating on the company, with a price target of $54. Executive...

Deutsche Bank trimmed its estimates and target price on Mylan NV (NASDAQ: MYL) shares following CEO Heather Bresch's Congressional testimony over the price hike of EpiPen allergy shots. Mylan raised the price of EpiPen, which accounts for 40 percent of its operating profits, to $600 for a two-pack...

A Federal District Court in Massachusetts recently issued a patent ruling that is "favorable" for Pfizer Inc. (NYSE: PFE), according to Gregg Gilbert of Deutsche Bank. As noted by Gilbert, the District Court ruled in favor of Pfizer and Celltrion and said that Johnson & Johnson (NYSE: JNJ)'s...